{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:16:58Z","timestamp":1790788618088,"version":"4.1.0"},"reference-count":287,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T00:00:00Z","timestamp":1614816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["401326337, SPP 2084"],"award-info":[{"award-number":["401326337, SPP 2084"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Radiotherapy and surgery are curative treatment options for localized prostate cancer (PCa) with a 5-year survival rate of nearly 100%. Once PCa cells spread into distant organs, such as bone, the overall survival rate of patients drops dramatically. The metastatic cascade and organotropism of PCa cells are regulated by different cellular subtypes, organ microenvironment, and their interactions. This cross-talk leads to pre-metastatic niche formation that releases chemo-attractive factors enforcing the formation of distant metastasis. Biological characteristics of PCa metastasis impacting on metastatic sites, burden, and latency is of clinical relevance. Therefore, the implementation of modern hybrid imaging technologies into clinical routine increased the sensitivity to detect metastases at earlier stages. This enlarged the number of PCa patients diagnosed with a limited number of metastases, summarized as oligometastatic disease. These patients can be treated with androgen deprivation in combination with local-ablative radiotherapy or radiopharmaceuticals directed to metastatic sites. Unfortunately, the number of patients with disease recurrence is high due to the enormous heterogeneity within the oligometastatic patient population and the lack of available biomarkers with predictive potential for metastasis-directed radiotherapy. Another, so far unmet clinical need is the diagnosis of minimal residual disease before onset of clinical manifestation and\/or early relapse after initial therapy. Here, monitoring of circulating and disseminating tumor cells in PCa patients during the course of radiotherapy may give us novel insight into how metastatic spread is influenced by radiotherapy and vice versa. In summary, this review critically compares current clinical concepts for metastatic PCa patients and discuss the implementation of recent preclinical findings improving our understanding of metastatic dissemination and radiotherapy resistance into standard of care.<\/jats:p>","DOI":"10.3389\/fonc.2020.627379","type":"journal-article","created":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T09:49:42Z","timestamp":1614851382000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":43,"title":["Metastatic Spread in Prostate Cancer Patients Influencing Radiotherapy Response"],"prefix":"10.3389","volume":"10","author":[{"given":"Daria","family":"Klusa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Lohaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Furesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Rauner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Bene\u0161ov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mechthild","family":"Krause","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ina","family":"Kurth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Peitzsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,3,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.0096","article-title":"Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial","volume":"5","author":"Fendler","year":"2019","journal-title":"JAMA Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.06.004","article-title":"Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial","volume":"74","author":"Siva","year":"2018","journal-title":"Eur Urol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.11.050","article-title":"Can Local Ablative Radiotherapy Revert Castration-resistant Prostate Cancer to an Earlier Stage of Disease","volume":"75","author":"Lohaus","year":"2019","journal-title":"Eur Urol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.4853","article-title":"Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial","volume":"36","author":"Ost","year":"2017","journal-title":"JCO"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-020-0134-x","article-title":"Molecular principles of metastasis: a hallmark of cancer revisited","volume":"5","author":"Fares","year":"2020","journal-title":"Signal Transduct Targeted Ther"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of Cancer: The Next Generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"B7","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nature17038","article-title":"Metastatic colonization by circulating tumour cells","volume":"529","author":"Massagu\u00e9","year":"2016","journal-title":"Nature"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/45.4.773","article-title":"Metastasis: Quantitative Analysis of Distribution and Fate of Tumor Emboli Labeled With 125I-5-Iodo-2\u2032 -deoxyuridine","volume":"45","author":"Fidler","year":"1970","journal-title":"J Natl Cancer Inst"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41698-019-0092-3","article-title":"Engineered models to parse apart the metastatic cascade","volume":"3","author":"Hapach","year":"2019","journal-title":"NPJ Precis Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)49915-0","article-title":"THE DISTRIBUTION OF SECONDARY GROWTHS IN CANCER OF THE BREAST","volume":"133","author":"Paget","year":"1889","journal-title":"Lancet"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.devcel.2019.04.012","article-title":"Metastasis Organotropism: Redefining the Congenial Soil","volume":"49","author":"Gao","year":"2019","journal-title":"Dev Cell"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1053\/hp.2000.6698","article-title":"Metastatic patterns of prostate cancer: An autopsy study of 1,589\u00a0patients","volume":"31","author":"Bubendorf","year":"2000","journal-title":"Hum Pathol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/pros.20889","article-title":"Survival in surgically treated, nodal positive prostate cancer patients is predicted by histopathological characteristics of the primary tumor and its lymph node metastases","volume":"69","author":"Fleischmann","year":"2009","journal-title":"Prostate"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-015-1607-3","article-title":"Validation of TNM classification for metastatic prostatic cancer treated using primary androgen deprivation therapy","volume":"34","author":"Kadono","year":"2016","journal-title":"World J Urol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.07.020","article-title":"Impact of the Site of Metastases on Survival in Patients with Metastatic Prostate Cancer","volume":"68","author":"Gandaglia","year":"2015","journal-title":"Eur Urol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2009.01.046","article-title":"Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy","volume":"55","author":"Da Pozzo","year":"2009","journal-title":"Eur Urol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.suronc.2009.02.008","article-title":"Regional lymph node staging in prostate cancer: prognostic and therapeutic implications","volume":"18","author":"Burkhard","year":"2009","journal-title":"Surg Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.11.023","article-title":"Phase III Trial of Long-Term Adjuvant Androgen Deprivation After Neoadjuvant Hormonal Cytoreduction and Radiotherapy in Locally Advanced Carcinoma of the Prostate: The Radiation Therapy Oncology Group Protocol 92\u201302","volume":"21","author":"Hanks","year":"2003","journal-title":"JCO"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.08.141","article-title":"Androgen Suppression Plus Radiation Versus Radiation Alone for Patients With Stage D1\/Pathologic Node-Positive Adenocarcinoma of the Prostate: Updated Results Based on National Prospective Randomized Trial Radiation Therapy Oncology Group 85-31","volume":"23","author":"Lawton","year":"2005","journal-title":"JCO"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/nri1919","article-title":"Tumour-induced immune modulation of sentinel lymph nodes","volume":"6","author":"Cochran","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1046\/j.1524-4741.2000.98114.x","article-title":"Selective Modulation of Paracortical Dendritic Cells and T-Lymphocytes in Breast Cancer Sentinel Lymph Nodes","volume":"6","author":"Huang","year":"2000","journal-title":"Breast J"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-015-1351-6","article-title":"The lymph node pre-metastatic niche","volume":"93","author":"Sleeman","year":"2015","journal-title":"J Mol Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13586","article-title":"Tumor necrosis factor-\u03b1 induces prostate cancer cell migration in lymphatic metastasis through CCR7 upregulation","volume":"109","author":"Maolake","year":"2018","journal-title":"Cancer Sci"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-018-0286-0","article-title":"Epithelial membrane protein 1 promotes tumor metastasis by enhancing cell migration via copine-III and Rac1","volume":"37","author":"Ahmat Amin","year":"2018","journal-title":"Oncogene"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1043\/2009-0114-OA.1","article-title":"Podoplanin expression in cancerous stroma induces lymphangiogenesis and predicts lymphatic spread and patient survival","volume":"134","author":"Kitano","year":"2010","journal-title":"Arch Pathol Lab Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2017.03.021","article-title":"Tenascin-C is a potential cancer-associated fibroblasts marker and predicts poor prognosis in prostate cancer","volume":"486","author":"Ni","year":"2017","journal-title":"Biochem Biophys Res Commun"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-03-0434","article-title":"Expression of Vascular Endothelial Growth Factor Receptor-3 by Lymphatic Endothelial Cells Is Associated with Lymph Node Metastasis in Prostate Cancer","volume":"10","author":"Zeng","year":"2004","journal-title":"Clin Cancer Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1745-7262.2006.00120.x","article-title":"Increased expressions of vascular endothelial growth factor (VEGF), VEGF-C and VEGF receptor-3 in prostate cancer tissue are associated with tumor progression","volume":"8","author":"Yang","year":"2006","journal-title":"Asian J Androl"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/pros.20276","article-title":"Expression of vascular endothelial growth factor C (VEGF-C) and VEGF receptor-3 in human prostate cancer is associated with regional lymph node metastasis","volume":"65","author":"Jennbacken","year":"2005","journal-title":"Prostate"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-1488","article-title":"Suppression of Prostate Cancer Nodal and Systemic Metastasis by Blockade of the Lymphangiogenic Axis","volume":"68","author":"Burton","year":"2008","journal-title":"Cancer Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-016-3134-3","article-title":"Phase 1 study of the anti-vascular endothelial growth factor receptor 3 monoclonal antibody LY3022856\/IMC-3C5 in patients with advanced and refractory solid tumors and advanced colorectal cancer","volume":"78","author":"Saif","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1634\/theoncologist.2018-0652","article-title":"Modulation of Premetastatic Niche by the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Pazopanib in Localized High-Risk Prostate Cancer Followed by Radical Prostatectomy: A Phase II Randomized Trial","volume":"23","author":"Maughan","year":"2018","journal-title":"Oncologist"},{"key":"B33","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4419-9129-4_13","article-title":"\u201cHistological, Immunophenotypic and Histomorphometric Characterization of Prostate Cancer Bone Metastases,\u201d","volume-title":"The Biology of Skeletal Metastases Cancer Treatment and Research","author":"Roudier","year":"2004"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41556-018-0145-9","article-title":"Metastatic niche functions and therapeutic opportunities","volume":"20","author":"Celi\u00e0-Terrassa","year":"2018","journal-title":"Nat Cell Biol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2018.02.025","article-title":"Parallels between hematopoietic stem cell and prostate cancer disseminated tumor cell regulation","volume":"119","author":"Cackowski","year":"2019","journal-title":"Bone"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s10585-013-9626-1","article-title":"Osteoblasts stimulate the osteogenic and metastatic progression of castration-resistant prostate cancer in a novel model for in vitro and in vivo studies","volume":"31","author":"Hagberg Thulin","year":"2014","journal-title":"Clin Exp Metastasis"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/9840962","article-title":"Prostate Osteoblast-Like Cells: A Reliable Prognostic Marker of Bone Metastasis in Prostate Cancer Patients","volume":"2018","author":"Scimeca","year":"2018","journal-title":"Contrast Media Mol Imaging"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1359\/JBMR.041109","article-title":"Skeletal localization and neutralization of the SDF-1(CXCL12)\/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo","volume":"20","author":"Sun","year":"2005","journal-title":"J Bone Miner Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S36109","article-title":"Emerging targets in cancer management: role of the CXCL12\/CXCR4 axis","volume":"6","author":"Cojoc","year":"2013","journal-title":"Onco Targets Ther"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1593\/neo.12324","article-title":"CXCR4 Inhibition with AMD3100 Sensitizes Prostate Cancer to Docetaxel Chemotherapy","volume":"14","author":"Domanska","year":"2012","journal-title":"Neoplasia"},{"key":"B41","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s12943-016-0552-0","article-title":"Pharmacological targeting of CXCL12\/CXCR4 signaling in prostate cancer bone metastasis","volume":"15","author":"Conley-LaComb","year":"2016","journal-title":"Mol Cancer"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.2300","article-title":"Prostate Cancer Cells Preferentially Home to Osteoblast-rich Areas in the Early Stages of Bone Metastasis: Evidence From In Vivo Models","volume":"29","author":"Wang","year":"2014","journal-title":"J Bone Mineral Res"},{"key":"B43","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1593\/neo.05694","article-title":"CXCR4 Chemokine Receptor Mediates Prostate Tumor Cell Adhesion through \u03b15 and \u03b23 Integrins","volume":"8","author":"Engl","year":"2006","journal-title":"Neoplasia"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-3016","article-title":"Cadherin-11 increases migration and invasion of prostate cancer cells and enhances their interaction with osteoblasts","volume":"70","author":"Huang","year":"2010","journal-title":"Cancer Res"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-08-0077","article-title":"Cadherin-11 Promotes the Metastasis of Prostate Cancer Cells to Bone","volume":"6","author":"Chu","year":"2008","journal-title":"Mol Cancer Res"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1359\/JBMR.050207","article-title":"Annexin II stimulates RANKL expression through MAPK","volume":"20","author":"Li","year":"2005","journal-title":"J Bone Miner Res"},{"key":"B47","doi-asserted-by":"publisher","first-page":"e107482","DOI":"10.1371\/journal.pone.0107482","article-title":"Impaired Osteoblast Differentiation in Annexin A2- and -A5-Deficient Cells","volume":"9","author":"Genetos","year":"2014","journal-title":"PloS One"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1186\/s12929-019-0497-x","article-title":"Emerging roles of gap junction proteins connexins in cancer metastasis, chemoresistance and clinical application","volume":"26","author":"Wu","year":"2019","journal-title":"J BioMed Sci"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.3449","article-title":"Connexin 43 expression is associated with increased malignancy in prostate cancer cell lines and functions to promote migration","volume":"6","author":"Zhang","year":"2015","journal-title":"Oncotarget"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-1451","article-title":"Molecular Pathways: MERTK Signaling in Cancer","volume":"19","author":"Cummings","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1593\/neo.91384","article-title":"GAS6\/AXL Axis Regulates Prostate Cancer Invasion, Proliferation, and Survival in the Bone Marrow Niche","volume":"12","author":"Shiozawa","year":"2010","journal-title":"Neoplasia"},{"key":"B52","doi-asserted-by":"publisher","first-page":"e61873","DOI":"10.1371\/journal.pone.0061873","article-title":"GAS6 Receptor Status Is Associated with Dormancy and Bone Metastatic Tumor Formation","volume":"8","author":"Taichman","year":"2013","journal-title":"PloS One"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1593\/neo.13402","article-title":"TBK1 Regulates Prostate Cancer Dormancy through mTOR Inhibition","volume":"15","author":"Kim","year":"2013","journal-title":"Neoplasia"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-1051","article-title":"Osteoblast-Secreted Factors Mediate Dormancy of Metastatic Prostate Cancer in the Bone via Activation of the TGF\u03b2RIII-p38MAPK-pS249\/T252RB Pathway","volume":"78","author":"Yu-Lee","year":"2018","journal-title":"Cancer Res"},{"key":"B55","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/s41568-020-0263-0","article-title":"The dormant cancer cell life cycle","volume":"20","author":"Phan","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-14-0199","article-title":"Castration-induced bone loss triggers growth of disseminated prostate cancer cells in bone","volume":"21","author":"Ottewell","year":"2014","journal-title":"Endocr-Relat Cancer"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(18)30047-0","article-title":"Bone health during endocrine therapy for cancer","volume":"6","author":"Rachner","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3816\/CGC.2007.n.003","article-title":"The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy","volume":"5","author":"Israeli","year":"2007","journal-title":"Clin Genitourin Cancer"},{"key":"B59","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1186\/2193-1801-3-586","article-title":"Zoledronic acid prevents decreases in bone mineral density in patients with prostate cancer undergoing combined androgen blockade","volume":"3","author":"Nishizawa","year":"2014","journal-title":"Springerplus"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00489-1","article-title":"Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data","volume":"17","author":"Vale","year":"2016","journal-title":"Lancet Oncol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"key":"B62","doi-asserted-by":"publisher","first-page":"LBA4507","DOI":"10.1200\/jco.2010.28.18_suppl.lba4507","article-title":"A randomized phase III trial of denosumab versus zoledronic acid in patients with bone metastases from castration-resistant prostate cancer","volume":"28","author":"Fizazi","year":"2010","journal-title":"JCO"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1177\/1756287216686018","article-title":"Denosumab treatment in the management of patients with advanced prostate cancer: clinical evidence and experience","volume":"9","author":"Hegemann","year":"2017","journal-title":"Ther Adv Urol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-018-0060-y","article-title":"Harnessing the potential of therapeutic agents to safeguard bone health in prostate cancer","volume":"21","author":"Miller","year":"2018","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf2784","article-title":"Metastasis as an evolutionary process","volume":"352","author":"Turajlic","year":"2016","journal-title":"Science"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2014.238","article-title":"Using tumour phylogenetics to identify the roots of metastasis in humans","volume":"12","author":"Naxerova","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1038\/nm.1944","article-title":"Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer","volume":"15","author":"Liu","year":"2009","journal-title":"Nat Med"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1172\/JCI70354","article-title":"Tracking the clonal origin of lethal prostate cancer","volume":"123","author":"Haffner","year":"2013","journal-title":"J Clin Invest"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1172\/JCI70935","article-title":"\u201cN of 1\u201d case reports in the era of whole-genome sequencing","volume":"123","author":"Brannon","year":"2013","journal-title":"J Clin Invest"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.10.025","article-title":"The Molecular Taxonomy of Primary Prostate Cancer","volume":"163","author":"Abeshouse","year":"2015","journal-title":"Cell"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Dan","year":"2015","journal-title":"Cell"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer","volume":"375","author":"Pritchard","year":"2016","journal-title":"New Engl J Med"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1038\/nature07943","article-title":"The cancer genome","volume":"458","author":"Stratton","year":"2009","journal-title":"Nature"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.cell.2018.03.029","article-title":"The Evolutionary Landscape of Localized Prostate Cancers Drives Clinical Aggression","volume":"173","author":"Espiritu","year":"2018","journal-title":"Cell"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1038\/nature12625","article-title":"The causes and consequences of genetic heterogeneity in cancer evolution","volume":"501","author":"Burrell","year":"2013","journal-title":"Nature"},{"key":"B76","doi-asserted-by":"publisher","first-page":"6605","DOI":"10.1038\/ncomms7605","article-title":"Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer","volume":"6","author":"Hong","year":"2015","journal-title":"Nat Commun"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2009.11.007","article-title":"Epithelial-Mesenchymal Transitions in Development and Disease","volume":"139","author":"Thiery","year":"2009","journal-title":"Cell"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1038\/nature14347","article-title":"The evolutionary history of lethal metastatic prostate cancer","volume":"520","author":"Gundem","year":"2015","journal-title":"Nature"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-1190","article-title":"Circulating Tumor Cells and Circulating Tumor DNA: Challenges and Opportunities on the Path to Clinical Utility","volume":"21","author":"Ignatiadis","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1038\/nrc4016","article-title":"Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer","volume":"15","author":"Watson","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-16-0049","article-title":"Clonal origin and spread of metastatic prostate cancer","volume":"23","author":"Etten","year":"2016","journal-title":"Endocr-Relat Cancer"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajur.2014.09.008","article-title":"History of the discovery and clinical translation of prostate-specific antigen","volume":"1","author":"Catalona","year":"2014","journal-title":"Asian J Urol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1503\/cmaj.060955","article-title":"Prostate-specific antigen in the early detection of prostate cancer","volume":"176","author":"Thompson","year":"2007","journal-title":"CMAJ: Can Med Assoc J"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.12.062","article-title":"Overdiagnosis and overtreatment of prostate cancer","volume":"65","author":"Loeb","year":"2014","journal-title":"Eur Urol"},{"key":"B85","first-page":"58","article-title":"Beyond Prostate-Specific Antigen: New Serologic Biomarkers for Improved Diagnosis and Management of Prostate Cancer","volume":"6","author":"Shariat","year":"2004","journal-title":"Rev Urol"},{"key":"B86","article-title":"Does prostate specific antigen density correlates with aggressiveness of the prostate cancer","volume":"13","author":"Saidi","year":"2009","journal-title":"Hippokratia"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djj410","article-title":"Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability","volume":"98","author":"Carter","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-1497.2000.90907.x","article-title":"Using the Free-to-total Prostate-specific Antigen Ratio to Detect Prostate Cancer in Men with Nonspecific Elevations of Prostate-specific Antigen Levels","volume":"15","author":"Hoffman","year":"2000","journal-title":"J Gen Intern Med"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjmsu.2011.08.006","article-title":"PSA velocity and doubling time in diagnosis and prognosis of prostate cancer","volume":"5","author":"Vickers","year":"2012","journal-title":"Br J Med Surg Urol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1186\/1748-717X-8-170","article-title":"A prostate-specific antigen doubling time of <6 months is prognostic for metastasis and prostate cancer-specific death for patients receiving salvage radiation therapy post radical prostatectomy","volume":"8","author":"Jackson","year":"2013","journal-title":"Radiat Oncol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx370.035","article-title":"PSA doubling time (PSADT) and proximal PSA predict metastasis-free survival (MFS) in men with biochemically recurrent prostate cancer (BRPC) after radical prostatectomy (RP): Implications for patient counseling and clinical trial design","volume":"28","author":"Markowski","year":"2017","journal-title":"Ann Oncol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv607","article-title":"Association between PSA kinetics and cancer-specific mortality in patients with localised prostate cancer: analysis of the placebo arm of the SPCG-6 study","volume":"27","author":"Thomsen","year":"2016","journal-title":"Ann Oncol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.3892\/mco.2016.1116","article-title":"Clinical significance of the prostate-specific antigen doubling time prior to and following radical prostatectomy to predict the outcome of prostate cancer","volume":"6","author":"Takeuchi","year":"2017","journal-title":"Mol Clin Oncol"},{"key":"B94","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.3390\/ijms20081813","article-title":"A Rich Array of Prostate Cancer Molecular Biomarkers: Opportunities and Challenges","volume":"20","author":"Kohaar","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12051312","article-title":"Insight into the Development of PET Radiopharmaceuticals for Oncology","volume":"12","author":"Lau","year":"2020","journal-title":"Cancers"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0990","article-title":"Imaging intratumor heterogeneity: role in therapy response, resistance, and clinical outcome","volume":"21","author":"O\u2019Connor","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-018-4079-z","article-title":"Impact of long-term androgen deprivation therapy on PSMA ligand PET\/CT in patients with castration-sensitive prostate cancer","volume":"45","author":"Afshar-Oromieh","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpet.2009.05.002","article-title":"FDG PET in Prostate Cancer","volume":"4","author":"Jadvar","year":"2009","journal-title":"PET Clin"},{"key":"B99","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41391-019-0174-x","article-title":"Lutetium-177 prostate-specific membrane antigen (PSMA) theranostics: practical nuances and intricacies","volume":"23","author":"Iravani","year":"2020","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-020-0202-x","article-title":"GLUT1 expression in high-risk prostate cancer: correlation with 18 F-FDG-PET\/CT and clinical outcome","volume":"23","author":"Meziou","year":"2020","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-005-1764-5","article-title":"Positron tomographic assessment of androgen receptors in prostatic carcinoma","volume":"32","author":"Dehdashti","year":"2005","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B102","doi-asserted-by":"publisher","first-page":"38S","DOI":"10.2967\/jnumed.115.169748","article-title":"Evaluation of Prostate Cancer with 11C- and 18F-Choline PET\/CT: Diagnosis and Initial Staging","volume":"57","author":"Nitsch","year":"2016","journal-title":"J Nucl Med"},{"key":"B103","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S0021-9258(19)50785-2","article-title":"The function of cytidine coenzymes in the biosynthesis of phospholipides","volume":"222","author":"Kennedy","year":"1956","journal-title":"J Biol Chem"},{"key":"B104","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s00259-007-0581-4","article-title":"The detection rate of [11C]choline-PET\/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer","volume":"35","author":"Krause","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-016-3329-1","article-title":"(18)F-FACBC (anti1-amino-3-(18)F-fluorocyclobutane-1-carboxylic acid) versus (11)C-choline PET\/CT in prostate cancer relapse: results of a prospective trial","volume":"43","author":"Nanni","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B106","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1053\/j.semnuclmed.2014.07.008","article-title":"Sodium 18F-Fluoride PET\/CT of Bone, Joint and Other Disorders","volume":"45","author":"Jadvar","year":"2015","journal-title":"Semin Nucl Med"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.162610","article-title":"Prospective Comparison of 99mTc-MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET\/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer","volume":"56","author":"Minamimoto","year":"2015","journal-title":"J Nucl Med"},{"key":"B108","article-title":"Overview of prostate-specific membrane antigen","author":"Chang","year":"2004","journal-title":"Rev Urol"},{"key":"B109","doi-asserted-by":"publisher","first-page":"4254","DOI":"10.1038\/s41598-018-22594-1","article-title":"PSMA expression: a potential ally for the pathologist in prostate cancer diagnosis","volume":"8","author":"Bravaccini","year":"2018","journal-title":"Sci Rep"},{"key":"B110","doi-asserted-by":"publisher","first-page":"17S","DOI":"10.2967\/jnumed.116.186775","article-title":"Glu-Ureido-Based Inhibitors of Prostate-Specific Membrane Antigen: Lessons Learned During the Development of a Novel Class of Low-Molecular-Weight Theranostic Radiotracers","volume":"58","author":"Kopka","year":"2017","journal-title":"J Nucl Med"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-014-2830-7","article-title":"89Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer","volume":"41","author":"Pandit-Taskar","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.176206","article-title":"First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake","volume":"57","author":"Pandit-Taskar","year":"2016","journal-title":"J Nucl Med"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.8b00940","article-title":"Prostate-Specific Membrane Antigen Targeted Gold Nanoparticles for Theranostics of Prostate Cancer","volume":"12","author":"Mangadlao","year":"2018","journal-title":"ACS Nano"},{"key":"B114","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/ph13010012","article-title":"Current Status of PSMA-Radiotracers for Prostate Cancer: Data Analysis of Prospective Trials Listed on ClinicalTrials.gov","volume":"13","author":"Zippel","year":"2020","journal-title":"Pharm (Basel)"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.0096","article-title":"Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial","volume":"5","author":"Fendler","year":"2019","journal-title":"JAMA Oncol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.226381","article-title":"A Prospective Study on 18F-DCFPyL PSMA PET\/CT Imaging in Biochemical Recurrence of Prostate Cancer","volume":"60","author":"Rousseau","year":"2019","journal-title":"J Nucl Med"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-017-3711-7","article-title":"Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET\/CT in patients with recurrent prostate cancer: evaluation in 1007 patients","volume":"44","author":"Afshar-Oromieh","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.01.049","article-title":"Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis","volume":"77","author":"Perera","year":"2020","journal-title":"Eur Urol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-019-04385-6","article-title":"Early lesion detection with 18F-DCFPyL PET\/CT in 248 patients with biochemically recurrent prostate cancer","volume":"46","author":"Wondergem","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.212233","article-title":"Detection Efficacy of 18F-PSMA-1007 PET\/CT in 251 Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy","volume":"60","author":"Giesel","year":"2019","journal-title":"J Nucl Med"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1007\/s11307-016-0957-6","article-title":"PSMA-Based [(18)F]DCFPyL PET\/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer","volume":"18","author":"Rowe","year":"2016","journal-title":"Mol Imaging Biol"},{"key":"B122","doi-asserted-by":"publisher","first-page":"58","DOI":"10.2967\/jnumed.119.226514","article-title":"Prospective Evaluation of PSMA-Targeted 18F-DCFPyL PET\/CT in Men with Biochemical Failure after Radical Prostatectomy for Prostate Cancer","volume":"61","author":"Rowe","year":"2019","journal-title":"J Nucl Med"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.7150\/thno.44584","article-title":"Immunohistochemical PSMA expression patterns of primary prostate cancer tissue are associated with the detection rate of biochemical recurrence with 68Ga-PSMA-11-PET","volume":"10","author":"Ferraro","year":"2020","journal-title":"Theranostics"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm058","article-title":"Gastrin-releasing peptide receptor as a molecular target in experimental anticancer therapy","volume":"18","author":"Cornelio","year":"2007","journal-title":"Ann Oncol"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.13.3.18696","article-title":"Fibroblast activation protein","volume":"13","author":"Liu","year":"2012","journal-title":"Cancer Biol Ther"},{"key":"B126","doi-asserted-by":"publisher","first-page":"e926295","DOI":"10.1155\/2013\/926295","article-title":"Peptide Receptor Targeting in Cancer: The Somatostatin Paradigm","volume":"2013","author":"Barbieri","year":"2013","journal-title":"Int J Peptides"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1053\/hp.2000.6698","article-title":"Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients","volume":"31","author":"Bubendorf","year":"2000","journal-title":"Hum Pathol"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3055","article-title":"Cancer to bone: a fatal attraction","volume":"11","author":"Weilbaecher","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.3892\/mco.2014.449","article-title":"Palliative effects and adverse events of strontium-89 for prostate cancer patients with bone metastasis","volume":"3","author":"Furubayashi","year":"2015","journal-title":"Mol Clin Oncol"},{"key":"B130","doi-asserted-by":"publisher","first-page":"1000131","DOI":"10.4172\/2161-1459.1000131","article-title":"Beyond Palliation: Therapeutic Applications of 153Samarium-EDTMP","volume":"3","author":"Wilky","year":"2013","journal-title":"Clin Exp Pharmacol"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S122417","article-title":"Radium 223 dichloride for prostate cancer treatment","volume":"11","author":"Deshayes","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70474-7","article-title":"Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial","volume":"15","author":"Hoskin","year":"2014","journal-title":"Lancet Oncol"},{"key":"B133","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s00259-016-3481-7","article-title":"177Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer: safety, efficacy, and quality of life assessment","volume":"44","author":"Yadav","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B134","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2967\/jnumed.116.183194","article-title":"German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients","volume":"58","author":"Rahbar","year":"2017","journal-title":"J Nucl Med"},{"key":"B135","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1007\/s00259-017-3895-x","article-title":"Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review","volume":"45","author":"von Eyben","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-017-3751-z","article-title":"177Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer","volume":"44","author":"Br\u00e4uer","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B137","doi-asserted-by":"publisher","first-page":"795","DOI":"10.2967\/jnumed.117.203539","article-title":"Targeted \u03b1-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Swimmer-Plot Analysis Suggests Efficacy Regarding Duration of Tumor Control","volume":"59","author":"Kratochwil","year":"2018","journal-title":"J Nucl Med"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.229229","article-title":"Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving 225Ac-PSMA-617 Radioligand Therapy","volume":"61","author":"Sathekge","year":"2020","journal-title":"J Nucl Med"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.178673","article-title":"225Ac-PSMA-617 for PSMA-Targeted \u03b1-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer","volume":"57","author":"Kratochwil","year":"2016","journal-title":"J Nucl Med"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-017-3681-9","article-title":"The impact of repeated cycles of radioligand therapy using [177Lu]Lu-PSMA-617 on renal function in patients with hormone refractory metastatic prostate cancer","volume":"44","author":"Yordanova","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.26789","article-title":"177Lu-PSMA radioligand therapy of predominant lymph node metastatic prostate cancer","volume":"10","author":"von Eyben","year":"2019","journal-title":"Oncotarget"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-017-3716-2","article-title":"Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [177Lu]Lu-PSMA-617","volume":"44","author":"Ahmadzadehfar","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30198-0","article-title":"[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study","volume":"19","author":"Hofman","year":"2018","journal-title":"Lancet Oncol"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.236414","article-title":"Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of 177Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer","volume":"61","author":"Violet","year":"2020","journal-title":"J Nucl Med"},{"key":"B145","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1007\/s00259-017-3895-x","article-title":"Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review","volume":"45","author":"von Eyben","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.234054","article-title":"Is the Vision of Radioligand Therapy for Prostate Cancer Becoming a Reality? An Overview of the Phase III VISION Trial and Its Importance for the Future of Theranostics","volume":"60","author":"Rahbar","year":"2019","journal-title":"J Nucl Med"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32598-4","article-title":"Radiotherapy for newly diagnosed oligometastatic prostate cancer","volume":"392","author":"Boeri","year":"2018","journal-title":"Lancet"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.09.008","article-title":"Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial","volume":"75","author":"Boev\u00e9","year":"2019","journal-title":"Eur Urol"},{"key":"B149","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1200\/jco.1995.13.1.8","article-title":"Oligometastases","volume":"13","author":"Hellman","year":"1995","journal-title":"J Clin Oncol"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31860","article-title":"Oligometastatic prostate cancer: Reality or figment of imagination","volume":"125","author":"Foster","year":"2019","journal-title":"Cancer"},{"key":"B151","doi-asserted-by":"publisher","first-page":"e173501","DOI":"10.1001\/jamaoncol.2017.3501","article-title":"Consolidative Radiotherapy for Limited Metastatic Non\u2013Small-Cell Lung Cancer","volume":"4","author":"Iyengar","year":"2018","journal-title":"JAMA Oncol"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.1449","article-title":"Pembrolizumab After Completion of Locally Ablative Therapy for Oligometastatic Non\u2013Small Cell Lung Cancer","volume":"5","author":"Bauml","year":"2019","journal-title":"JAMA Oncol"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30532-0","article-title":"Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study","volume":"17","author":"Gomez","year":"2016","journal-title":"Lancet Oncol"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00201","article-title":"Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study","volume":"37","author":"Gomez","year":"2019","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.1808","article-title":"Efficacy and Safety of Locoregional Radiotherapy With Chemotherapy vs Chemotherapy Alone in De Novo Metastatic Nasopharyngeal Carcinoma","volume":"6","author":"You","year":"2020","journal-title":"JAMA Oncol"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31860","article-title":"Oligometastatic prostate cancer: Reality or figment of imagination","volume":"125","author":"Foster","year":"2019","journal-title":"Cancer"},{"key":"B158","doi-asserted-by":"publisher","first-page":"S2588-9311(20)30058-4","DOI":"10.1016\/j.euo.2020.05.004","article-title":"Metastasis-directed Therapy Prolongs Efficacy of Systemic Therapy and Improves Clinical Outcomes in Oligoprogressive Castration-resistant Prostate Cancer","author":"Deek","year":"2020","journal-title":"Eur Urol Oncol"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.06.021","article-title":"Sensitivity, Specificity, and Predictors of Positive 68Ga\u2013Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis","volume":"70","author":"Perera","year":"2016","journal-title":"Eur Urol"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0793","article-title":"Phase II trial of ipilimumab with stereotactic radiation therapy for metastatic disease: Outcomes, toxicities, and low-dose radiation-related abscopal responses","volume":"7","author":"Welsh","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.01.049","article-title":"Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer\u2014Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis","volume":"77","author":"Perera","year":"2020","journal-title":"Eur Urol"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70510-7","article-title":"Stereotactic body radiotherapy for oligometastases","volume":"14","author":"Tree","year":"2013","journal-title":"Lancet Oncol"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.17.1591","article-title":"Natural History of Progression After PSA Elevation Following Radical Prostatectomy","volume":"281","author":"Pound","year":"1999","journal-title":"JAMA"},{"key":"B164","doi-asserted-by":"publisher","first-page":"JCO2000348","DOI":"10.1200\/JCO.20.00348","article-title":"Exploring Spatial-Temporal Changes in 18F-Sodium Fluoride PET\/CT and Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide","volume":"38","author":"Kyriakopoulos","year":"2020","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2015.05.021","article-title":"Palliative pelvic radiotherapy for symptomatic incurable prostate cancer \u2013 A prospective multicenter study","volume":"115","author":"Cameron","year":"2015","journal-title":"Radiother Oncol"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.4853","article-title":"Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial","volume":"36","author":"Ost","year":"2018","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"B168","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.eururo.2017.06.002","article-title":"Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017","volume":"73","author":"Gillessen","year":"2018","journal-title":"Eur Urol"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3","volume":"34","author":"Scher","year":"2016","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.07.009","article-title":"Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherapy and Elective Nodal Radiotherapy","volume":"76","author":"De Bleser","year":"2019","journal-title":"Eur Urol"},{"key":"B171","doi-asserted-by":"publisher","first-page":"S2405-4569(19)30270-6","DOI":"10.1016\/j.euf.2019.08.012","article-title":"Prostate-specific Membrane Antigen Positron Emission Tomography\u2013detected Oligorecurrent Prostate Cancer Treated with Metastases-directed Radiotherapy: Role of Addition and Duration of Androgen Deprivation","author":"Kroeze","year":"2019","journal-title":"Eur Urol Focus"},{"key":"B172","doi-asserted-by":"publisher","first-page":"88","DOI":"10.2967\/jnumed.120.245456","article-title":"PSMA-ligand PET for early castration-resistant prostate cancer: a retrospective single-center study","volume":"62","author":"Weber","year":"2020","journal-title":"J Nucl Med"},{"key":"B173","doi-asserted-by":"publisher","first-page":"S2588-9311(20)30058-4","DOI":"10.1016\/j.euo.2020.05.004","article-title":"Metastasis-directed Therapy Prolongs Efficacy of Systemic Therapy and Improves Clinical Outcomes in Oligoprogressive Castration-resistant Prostate Cancer","author":"Deek","year":"2020","journal-title":"Eur Urol Oncol"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2019.06.011","article-title":"Progressive Site-Directed Therapy for Castration-Resistant Prostate Cancer: Localization of the Progressive Site as a Prognostic Factor","volume":"105","author":"Yoshida","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.11.050","article-title":"Can Local Ablative Radiotherapy Revert Castration-resistant Prostate Cancer to an Earlier Stage of Disease","volume":"75","author":"Lohaus","year":"2019","journal-title":"Eur Urol"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-019-02717-7","article-title":"Metastasis-directed stereotactic radiotherapy for oligoprogressive castration-resistant prostate cancer: a multicenter study","volume":"37","author":"Triggiani","year":"2019","journal-title":"World J Urol"},{"key":"B177","doi-asserted-by":"publisher","first-page":"819362","DOI":"10.1155\/2014\/819362","article-title":"Detection of Circulating Tumor Cells","volume":"2014","author":"de Wit","year":"2014","journal-title":"Scientifica (Cairo)"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2012.194258","article-title":"Circulating Tumor Cells: Liquid Biopsy of Cancer","volume":"59","author":"Alix-Panabi\u00e8res","year":"2013","journal-title":"Clin Chem"},{"key":"B179","first-page":"146","article-title":"A Case of Cancer in Which Cells Similar to Those in the Tumours Were Seen in the Blood after Death","volume":"14","author":"Ashworth","year":"1869","journal-title":"Aust Med J"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1091\/mbc.e08-10-1076","article-title":"ZEB1 Enhances Transendothelial Migration and Represses the Epithelial Phenotype of Prostate Cancer Cells","volume":"20","author":"Drake","year":"2009","journal-title":"MBoC"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1111\/iju.14488","article-title":"Do Circulating Tumor Cell Numbers Increase in Prostate Cancer Patients after Attentive DRE or Robot Assisted Prostatectomy","author":"Smith","year":"2021","journal-title":"Int J Urol"},{"key":"B182","doi-asserted-by":"publisher","first-page":"C1","DOI":"10.1152\/ajpcell.00238.2015","article-title":"Tumor cell intravasation","volume":"311","author":"Chiang","year":"2016","journal-title":"Am J Physiol Cell Physiol"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2009.090384","article-title":"Comparative analysis of metastasis variants derived from human prostate carcinoma cells: roles in intravasation of VEGF-mediated angiogenesis and uPA-mediated invasion","volume":"175","author":"Conn","year":"2009","journal-title":"Am J Pathol"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3628","article-title":"Crossing the endothelial barrier during metastasis","volume":"13","author":"Reymond","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2014.10.031","article-title":"Cancer cells remodel themselves and vasculature to overcome the endothelial barrier","volume":"380","author":"Shenoy","year":"2016","journal-title":"Cancer Lett"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2018.03.092","article-title":"Platelets Promote Metastasis via Binding Tumor CD97 Leading to Bidirectional Signaling that Coordinates Transendothelial Migration","volume":"23","author":"Ward","year":"2018","journal-title":"Cell Rep"},{"key":"B187","doi-asserted-by":"publisher","first-page":"835","DOI":"10.3390\/cancers11060835","article-title":"Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1\/PD-L1 Inhibitors","volume":"11","author":"Janning","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2014.07.013","article-title":"Circulating Tumor Cell Clusters are Oligoclonal Precursors of Breast Cancer Metastasis","volume":"158","author":"Aceto","year":"2014","journal-title":"Cell"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-1110","article-title":"Circulating Tumor Cells in Patients with Breast Cancer Dormancy","volume":"10","author":"Meng","year":"2004","journal-title":"Clin Cancer Res"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.7_suppl.243","article-title":"The effect of a structured exercise intervention on CTCs and platelet cloaking in patients with metastatic prostate cancer","volume":"37","author":"Brady","year":"2019","journal-title":"JCO"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-0915-y","article-title":"Neutrophils escort circulating tumour cells to enable cell cycle progression","volume":"566","author":"Szczerba","year":"2019","journal-title":"Nature"},{"key":"B192","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.1016\/j.celrep.2019.07.102","article-title":"Metastatic Tumor Cells Exploit Their Adhesion Repertoire to Counteract Shear Forces during Intravascular Arrest","volume":"28","author":"Osmani","year":"2019","journal-title":"Cell Rep"},{"key":"B193","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.devcel.2018.02.015","article-title":"Hemodynamic Forces Tune the Arrest, Adhesion, and Extravasation of Circulating Tumor Cells","volume":"45","author":"Follain","year":"2018","journal-title":"Dev Cell"},{"key":"B194","doi-asserted-by":"publisher","first-page":"e85143","DOI":"10.1371\/journal.pone.0085143","article-title":"Circulating Tumor Cells from Prostate Cancer Patients Interact with E-Selectin under Physiologic Blood Flow","volume":"8","author":"Gakhar","year":"2013","journal-title":"PloS One"},{"key":"B195","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1038\/s41467-020-15886-6","article-title":"Mapping the spreading routes of lymphatic metastases in human colorectal cancer","volume":"11","author":"Zhang","year":"2020","journal-title":"Nat Commun"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2623-z","article-title":"Lymph protects metastasizing melanoma cells from ferroptosis","volume":"585","author":"Ubellacker","year":"2020","journal-title":"Nature"},{"key":"B197","doi-asserted-by":"publisher","first-page":"13579","DOI":"10.1038\/s41598-019-49964-7","article-title":"Interfocal heterogeneity challenges the clinical usefulness of molecular classification of primary prostate cancer","volume":"9","author":"Carm","year":"2019","journal-title":"Sci Rep"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2012.185","article-title":"The complexity of prostate cancer: genomic alterations and heterogeneity","volume":"9","author":"Boyd","year":"2012","journal-title":"Nat Rev Urol"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.7_suppl.46","article-title":"The impact of intratumoral heterogeneity on prognostic biomarkers in localized prostate cancer","volume":"37","author":"Brastianos","year":"2019","journal-title":"JCO"},{"key":"B200","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.1200\/EDBK_175524","article-title":"Tumor Evolution, Heterogeneity, and Therapy for Our Patients With Advanced Cancer: How Far Have We Come","volume":"37","author":"El-Deiry","year":"2017","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.01.018","article-title":"Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future","volume":"168","author":"McGranahan","year":"2017","journal-title":"Cell"},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0862","article-title":"Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis","volume":"24","author":"Lambros","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B203","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1373\/clinchem.2017.275503","article-title":"Multiplex Gene Expression Profiling of In Vivo Isolated Circulating Tumor Cells in High-Risk Prostate Cancer Patients","volume":"64","author":"Markou","year":"2018","journal-title":"Clin Chem"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2016.260299","article-title":"Accession of Tumor Heterogeneity by Multiplex Transcriptome Profiling of Single Circulating Tumor Cells","volume":"62","author":"Gorges","year":"2016","journal-title":"Clin Chem"},{"key":"B205","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.11191","article-title":"Technical challenges in the isolation and analysis of circulating tumor cells","volume":"7","author":"van der Toom","year":"2016","journal-title":"Oncotarget"},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2019.01.006","article-title":"Liquid Biopsies in Cancer Diagnosis, Monitoring, and Prognosis","volume":"40","author":"Rubis","year":"2019","journal-title":"Trends Pharmacol Sci"},{"key":"B207","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.14","article-title":"Integrating liquid biopsies into the management of cancer","volume":"14","author":"Siravegna","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-017-1105-2","article-title":"Circulating tumor cells: clinical validity and utility","volume":"22","author":"Cabel","year":"2017","journal-title":"Int J Clin Oncol"},{"key":"B209","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.10396","article-title":"Phenotypic and genetic heterogeneity of tumor tissue and circulating tumor cells in patients with metastatic castration-resistant prostate cancer: A report from the PETRUS prospective study","volume":"7","author":"Massard","year":"2016","journal-title":"Oncotarget"},{"key":"B210","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-1353","article-title":"Phenotypic Heterogeneity of Circulating Tumor Cells Informs Clinical Decisions between AR Signaling Inhibitors and Taxanes in Metastatic Prostate Cancer","volume":"77","author":"Scher","year":"2017","journal-title":"Cancer Res"},{"key":"B211","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.04.006","article-title":"Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer","volume":"76","author":"Sharp","year":"2019","journal-title":"Eur Urol"},{"key":"B212","doi-asserted-by":"publisher","DOI":"10.1039\/c9an00999j","article-title":"Expression pattern of androgen receptors, AR-V7 and AR-567es, in circulating tumor cells and paired plasma-derived extracellular vesicles in metastatic castration resistant prostate cancer","volume":"144","author":"Strati","year":"2019","journal-title":"Analyst"},{"key":"B213","doi-asserted-by":"publisher","first-page":"036003","DOI":"10.1088\/1478-3975\/ab073a","article-title":"Androgen receptor nuclear localization correlates with AR-V7 mRNA expression in circulating tumor cells (CTCs) from metastatic castration resistance prostate cancer patients","volume":"16","author":"Worroll","year":"2019","journal-title":"Phys Biol"},{"key":"B214","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nm.4045","article-title":"Divergent clonal evolution of castration resistant neuroendocrine prostate cancer","volume":"22","author":"Beltran","year":"2016","journal-title":"Nat Med"},{"key":"B215","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.6330","article-title":"A comparison of isolated circulating tumor cells and tissue biopsies using whole-genome sequencing in prostate cancer","volume":"6","author":"Jiang","year":"2015","journal-title":"Oncotarget"},{"key":"B216","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12967-017-1138-3","article-title":"Circulating tumor cells capture disease evolution in advanced prostate cancer","volume":"15","author":"Lack","year":"2017","journal-title":"J Trans Med"},{"key":"B217","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-4100","article-title":"Single-Cell Circulating Tumor Cell Analysis Reveals Genomic Instability as a Distinctive Feature of Aggressive Prostate Cancer","volume":"26","author":"Malihi","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B218","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.euo.2018.12.005","article-title":"An Accessible and Unique Insight into Metastasis Mutational Content Through Whole-exome Sequencing of Circulating Tumor Cells in Metastatic Prostate Cancer","volume":"3","author":"Faugeroux","year":"2020","journal-title":"Eur Urol Oncol"},{"key":"B219","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29455","article-title":"Subclassification of prostate cancer circulating tumor cells by nuclear size reveals very small nuclear circulating tumor cells in patients with visceral metastases","volume":"121","author":"Chen","year":"2015","journal-title":"Cancer"},{"key":"B220","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.55.3487","article-title":"Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer","volume":"33","author":"Scher","year":"2015","journal-title":"J Clin Oncol"},{"key":"B221","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-3202","article-title":"Report from the SWOG Radiation Oncology Committee: Research Objectives Workshop 2017","volume":"24","author":"Okunieff","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B222","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-0872","article-title":"Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer","volume":"14","author":"de Bono","year":"2008","journal-title":"Clin Cancer Res"},{"key":"B223","doi-asserted-by":"publisher","DOI":"10.1038\/pcan.2015.36","article-title":"The significance of circulating tumor cells in prostate cancer patients undergoing adjuvant or salvage radiation therapy","volume":"18","author":"Lowes","year":"2015","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"B224","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.2998","article-title":"Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials","volume":"36","author":"Heller","year":"2017","journal-title":"JCO"},{"key":"B225","doi-asserted-by":"publisher","first-page":"676","DOI":"10.3390\/cells8070676","article-title":"Clinical Impact of Circulating Tumor Cells in Patients with Localized Prostate Cancer","volume":"8","author":"Broncy","year":"2019","journal-title":"Cells"},{"key":"B226","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s13014-020-01577-5","article-title":"Detection and dynamics of circulating tumor cells in patients with high-risk prostate cancer treated with radiotherapy and hormones: a prospective phase II study","volume":"15","author":"Zapatero","year":"2020","journal-title":"Radiat Oncol"},{"key":"B227","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1186\/s12885-019-5977-6","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial","volume":"19","author":"Palma","year":"2019","journal-title":"BMC Cancer"},{"key":"B228","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-019-5977-6","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): Study protocol for a randomized phase III trial","volume":"19","author":"Palma","year":"2019","journal-title":"BMC Cancer"},{"key":"B229","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1224","article-title":"The added value of circulating tumor cell enumeration to standard markers in assessing prognosis in a metastatic castration-resistant prostate cancer population","volume":"23","author":"Heller","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B230","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.55.3487","article-title":"Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer","volume":"33","author":"Scher","year":"2015","journal-title":"J Clin Oncol"},{"key":"B231","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1158\/1541-7786.MCR-10-0490","article-title":"Circulating Tumor Cells from Patients with Advanced Prostate and Breast Cancer Display Both Epithelial and Mesenchymal Markers","volume":"9","author":"Armstrong","year":"2011","journal-title":"Mol Cancer Res"},{"key":"B232","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.3390\/cancers12071930","article-title":"Circulating Tumor Cell Detection Technologies and Clinical Utility: Challenges and Opportunities","volume":"12","author":"Habli","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B233","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.51.7417","article-title":"Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer","volume":"32","author":"Goldkorn","year":"2014","journal-title":"J Clin Oncol"},{"key":"B234","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29212","article-title":"Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial","volume":"136","author":"Goldkorn","year":"2015","journal-title":"Int J Cancer"},{"key":"B235","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.eururo.2011.07.011","article-title":"TMPRSS2-ERG Status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate","volume":"60","author":"Danila","year":"2011","journal-title":"Eur Urol"},{"key":"B236","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601532","article-title":"Detection of HER-2\/neu-positive circulating epithelial cells in prostate cancer patients","volume":"90","author":"Ady","year":"2004","journal-title":"Br J Cancer"},{"key":"B237","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00582","article-title":"New Screening Test Improves Detection of Prostate Cancer Using Circulating Tumor Cells and Prostate-Specific Markers","volume":"10","author":"Ried","year":"2020","journal-title":"Front Oncol"},{"key":"B238","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.04.006","article-title":"Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer","volume":"76","author":"Sharp","year":"2019","journal-title":"Eur Urol"},{"key":"B239","doi-asserted-by":"publisher","DOI":"10.1039\/c9an00999j","article-title":"Expression pattern of androgen receptors, AR-V7 and AR-567es, in circulating tumor cells and paired plasma-derived extracellular vesicles in metastatic castration resistant prostate cancer","volume":"144","author":"Strati","year":"2019","journal-title":"Analyst"},{"key":"B240","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.12529","article-title":"AR splice variants in circulating tumor cells of patients with castration-resistant prostate cancer: relation with outcome to cabazitaxel","volume":"13","author":"Sieuwerts","year":"2019","journal-title":"Mol Oncol"},{"key":"B241","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0320","article-title":"Expression of AR-V7 and ARV 567Es in circulating tumor cells correlates with outcomes to taxane therapy in men with metastatic prostate cancer treated in taxynergy","volume":"25","author":"Tagawa","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B242","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1158\/2159-8290.CD-16-1406","article-title":"An RNA-based digital circulating tumor cell signature is predictive of drug response and early dissemination in prostate cancer","volume":"8","author":"Miyamoto","year":"2018","journal-title":"Cancer Discovery"},{"key":"B243","doi-asserted-by":"publisher","DOI":"10.1001\/jama.294.4.433","article-title":"Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy","volume":"294","author":"Freedland","year":"2005","journal-title":"JAMA"},{"key":"B244","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000000346","article-title":"Personalized Risks of Over Diagnosis for Screen Detected Prostate Cancer Incorporating Patient Comorbidities: Estimation and Communication","volume":"202","author":"Gulati","year":"2019","journal-title":"J Urol"},{"key":"B245","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)67149-2","article-title":"Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline","volume":"164","author":"Berruti","year":"2000","journal-title":"J Urol"},{"key":"B246","doi-asserted-by":"publisher","DOI":"10.1111\/febs.14325","article-title":"Innate and Acquired Immune Surveillance in the Post-Dissemination Phase of Metastasis","volume":"285","author":"Gonzalez","year":"2018","journal-title":"FEBS J"},{"key":"B247","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.144","article-title":"Circulating and disseminated tumour cells \u2014 mechanisms of immune surveillance and escape","volume":"14","author":"Mohme","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"B248","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-1754","article-title":"Disseminated tumor cells in prostate cancer patients after radical prostatectomy and without evidence of disease predicts biochemical recurrence","volume":"15","author":"Morgan","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B249","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2018.01.033","article-title":"Prostate Cancer Disseminated Tumor Cells are Rarely Detected in the Bone Marrow of Localized Patients Undergoing Radical Prostatectomy Across Multiple Rare Cell Detection Platforms","volume":"199","author":"Chalfin","year":"2018","journal-title":"J Urol"},{"key":"B250","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.2480","article-title":"Characterization of single disseminated prostate cancer cells\u00a0reveals tumor cell heterogeneity and identifies dormancy associated pathways","volume":"5","author":"Ch\u00e9ry","year":"2014","journal-title":"Oncotarget"},{"key":"B251","doi-asserted-by":"publisher","DOI":"10.1002\/pros.23896","article-title":"Detection and isolation of disseminated tumor cells in bone marrow of patients with clinically localized prostate cancer","volume":"79","author":"Cackowski","year":"2019","journal-title":"Prostate"},{"key":"B252","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-2505","article-title":"Hematopoietic Stem Cell Niche Is a Potential Therapeutic Target for Bone Metastatic Tumors","volume":"17","author":"Shiozawa","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B253","doi-asserted-by":"publisher","DOI":"10.1172\/JCI43414","article-title":"Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow","volume":"121","author":"Shiozawa","year":"2011","journal-title":"J Clin Invest"},{"key":"B254","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-18-0718","article-title":"AXL Is a Putative Tumor Suppressor and Dormancy Regulator in Prostate Cancer","volume":"17","author":"Axelrod","year":"2019","journal-title":"Mol Cancer Res"},{"key":"B255","doi-asserted-by":"publisher","first-page":"36520","DOI":"10.1038\/srep36520","article-title":"Axl is required for TGF-\u03b22-induced dormancy of prostate cancer cells in the bone marrow","volume":"6","author":"Yumoto","year":"2016","journal-title":"Sci Rep"},{"key":"B256","doi-asserted-by":"publisher","first-page":"e50162","DOI":"10.15252\/embr.202050162","article-title":"Prostate cancer cell-intrinsic interferon signaling regulates dormancy and metastatic outgrowth in bone","volume":"21","author":"Owen","year":"2020","journal-title":"EMBO Rep"},{"key":"B257","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-14-0199","article-title":"Castration-induced bone loss triggers growth of disseminated prostate cancer cells in bone","volume":"21","author":"Ottewell","year":"2014","journal-title":"Endocr-Relat Cancer"},{"key":"B258","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-17-0132","article-title":"Sympathetic Signaling Reactivates Quiescent Disseminated Prostate Cancer Cells in the Bone Marrow","volume":"15","author":"Decker","year":"2017","journal-title":"Mol Cancer Res"},{"key":"B259","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2009.11.025","article-title":"Tumor self-seeding by circulating cancer cells","volume":"139","author":"Kim","year":"2009","journal-title":"Cell"},{"key":"B260","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2009.12.013","article-title":"Tumor Self-Seeding: Bidirectional Flow of Tumor Cells","volume":"139","author":"Leung","year":"2009","journal-title":"Cell"},{"key":"B261","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-019-1795-7","article-title":"Self-seeding circulating tumor cells promote the proliferation and metastasis of human osteosarcoma by upregulating interleukin-8","volume":"10","author":"Liu","year":"2019","journal-title":"Cell Death Dis"},{"key":"B262","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.04.036","article-title":"Treatment of the Primary Tumor in Metastatic Prostate Cancer: Current Concepts and Future Perspectives","volume":"69","author":"Bayne","year":"2016","journal-title":"Eur Urol"},{"key":"B263","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32486-3","article-title":"Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial","volume":"392","author":"Parker","year":"2018","journal-title":"Lancet"},{"key":"B264","doi-asserted-by":"publisher","first-page":"934","DOI":"10.3332\/ecancer.2019.934","article-title":"Subtypes of minimal residual disease, association with Gleason score, risk and time to biochemical failure in pT2 prostate cancer treated with radical prostatectomy","volume":"13","author":"Murray","year":"2019","journal-title":"Ecancermedicalscience"},{"key":"B265","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s40659-018-0180-9","article-title":"Minimal residual disease in prostate cancer patients after primary treatment: theoretical considerations, evidence and possible use in clinical management","volume":"51","author":"Murray","year":"2018","journal-title":"Biol Res"},{"key":"B266","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1807256115","article-title":"Criticality in tumor evolution and clinical outcome","volume":"115","author":"Persi","year":"2018","journal-title":"PNAS"},{"key":"B267","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types","volume":"51","author":"Samstein","year":"2019","journal-title":"Nat Genet"},{"key":"B268","doi-asserted-by":"publisher","first-page":"5251","DOI":"10.1038\/s41467-019-13084-7","article-title":"The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact","volume":"10","author":"van Dessel","year":"2019","journal-title":"Nat Commun"},{"key":"B269","doi-asserted-by":"publisher","first-page":"djx118","DOI":"10.1093\/jnci\/djx118","article-title":"Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer","volume":"109","author":"Wyatt","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"B270","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.a.23571","article-title":"The ParsortixTM Cell Separation System-A versatile liquid biopsy platform","volume":"93","author":"Miller","year":"2018","journal-title":"Cytom A"},{"key":"B271","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.a.23687","article-title":"DEPArrayTM system: An automatic image-based sorter for isolation of pure circulating tumor cells","volume":"93","author":"Di Trapani","year":"2018","journal-title":"Cytom A"},{"key":"B272","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.a.23507","article-title":"ClearCell\u00ae FX, a label-free microfluidics technology for enrichment of viable circulating tumor cells","volume":"93","author":"Lee","year":"2018","journal-title":"Cytom A"},{"key":"B273","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/nmeth.3281","article-title":"Real-time deformability cytometry: on-the-fly cell mechanical phenotyping","volume":"12","author":"Otto","year":"2015","journal-title":"Nat Methods"},{"key":"B274","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-020-0237-z","article-title":"Clinical utility of the exosome based ExoDx Prostate( IntelliScore ) EPI test in men presenting for initial Biopsy with a PSA 2\u201310 ng\/mL","volume":"23","author":"Tutrone","year":"2020","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"B275","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1805966","article-title":"Metastasis-free Survival \u2014 A New End Point in Prostate Cancer Trials","volume":"378","author":"Beaver","year":"2018","journal-title":"New Engl J Med"},{"key":"B276","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1158\/1541-7786.MCR-14-0118","article-title":"Annexin 2\u2013CXCL12 Interactions Regulate Metastatic Cell Targeting and Growth in the Bone Marrow","volume":"13","author":"Jung","year":"2015","journal-title":"Mol Cancer Res"},{"key":"B277","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.cell.2016.02.025","article-title":"Metastatic Latency and Immune Evasion through Autocrine Inhibition of WNT","volume":"165","author":"Malladi","year":"2016","journal-title":"Cell"},{"key":"B278","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)04046-0","article-title":"Inflammation and cancer: back to Virchow","volume":"357","author":"Balkwill","year":"2001","journal-title":"Lancet"},{"key":"B279","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/nri3789","article-title":"Immune cell promotion of metastasis","volume":"15","author":"Kitamura","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B280","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.cell.2010.03.014","article-title":"Macrophage Diversity Enhances Tumor Progression and Metastasis","volume":"141","author":"Qian","year":"2010","journal-title":"Cell"},{"key":"B281","doi-asserted-by":"publisher","DOI":"10.1002\/pros.23742","article-title":"M2 macrophages and regulatory T cells in lethal prostate cancer","volume":"79","author":"Erlandsson","year":"2019","journal-title":"Prostate"},{"key":"B282","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.1016\/j.celrep.2019.07.068","article-title":"Re-education of Tumor-Associated Macrophages by CXCR2 Blockade Drives Senescence and Tumor Inhibition in Advanced Prostate Cancer","volume":"28","author":"Di Mitri","year":"2019","journal-title":"Cell Rep"},{"key":"B283","article-title":"Tumor associated macrophages enhance the establishment and growth of prostate cancer bone metastasis","volume":"67","author":"Kim","year":"2007","journal-title":"Cancer Res"},{"key":"B284","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/imm.12938","article-title":"The role of transforming growth factor \u03b2 in T helper 17 differentiation","volume":"155","author":"Zhang","year":"2018","journal-title":"Immunology"},{"key":"B285","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/j.cell.2019.10.029","article-title":"Differences in Tumor Microenvironment Dictate T Helper Lineage Polarization and Response to Immune Checkpoint Therapy","volume":"179","author":"Jiao","year":"2019","journal-title":"Cell"},{"key":"B286","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/EDBK_278853","article-title":"Immune Checkpoint Blockade for Prostate Cancer: Niche Role or Next Breakthrough","volume":"40","author":"de Almeida","year":"2020","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B287","doi-asserted-by":"publisher","DOI":"10.1002\/mc.23192","article-title":"Human prostate cancer bone metastases have an actionable immunosuppressive microenvironment","volume":"59","author":"Baryawno","year":"2020","journal-title":"Mol Carcinog"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2020.627379\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T09:49:50Z","timestamp":1614851390000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2020.627379\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,4]]},"references-count":287,"alternative-id":["10.3389\/fonc.2020.627379"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2020.627379","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,4]]},"article-number":"627379"}}